The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Theranos’s day in court & AbbVie’s post-Humira future

By Meghana Keshavan

The READOUT
The Readout

Bad news for novel pain drugs & biotech feels the Bern

By Damian Garde

The READOUT
The Readout

The rise of ‘hypelines’ & the allure of billion-dollar buyouts

By Damian Garde

The READOUT
The Readout

Advocating for scientific taboo & a nagging trend in IPOs

By Damian Garde

The READOUT
The Readout

The state of the NASH race & a (relatively) new idea in Alzheimer’s

By Damian Garde

The READOUT
The Readout

Bickering Democrats & data from Alnylam

By Meghana Keshavan

The READOUT
The Readout

Azar in his own words & decision day for Bristol-Myers

By Damian Garde

The READOUT
The Readout

Gilead’s future & an Amgen vs. Novartis wrinkle

By Damian Garde

The READOUT
The Readout

Azar’s uphill battle and the limits of genomics

By Damian Garde

The READOUT
The Readout

A wily gene therapy target & a biopharma sea change

By Damian Garde

The READOUT
The Readout

Join our STAT Plus chat, Biotech, AMA-style

By Damian Garde

The READOUT
The Readout

BioCryst’s pending readout & PBMs go to Washington

By Meghana Keshavan

The READOUT
The Readout

The latest angst over Chinese investment & Scott Gottlieb’s ‘tweetastic’ farewell

By Damian Garde

The READOUT
The Readout

Soon-Shiong’s alleged scheme & Gottlieb’s next chapter

By Damian Garde

The READOUT
The Readout

Making sense of the DNA test boom & Sangamo’s sigh of relief

By Damian Garde

The READOUT
The Readout

Biogen’s big decision & biotech’s rat advocate

By Damian Garde

The READOUT
The Readout

Alzheimer’s patients react & Parker posts pancreatic cancer results

By Meghana Keshavan

The READOUT
The Readout

Wall Street deal whisperers & Biogen’s chance to explain

By Damian Garde

The READOUT
The Readout

Bristol-Myers bets on AI & biotech frets election season

By Damian Garde

The READOUT
The Readout

Bristol-Myers’ week of reckoning & a novel way to raise cash in biotech

By Damian Garde

The READOUT
The Readout

An encouraging word in Alzheimer’s & Biogen’s latest angst

By Damian Garde

The READOUT
The Readout

The soaring costs of esketamine & some insulin transparency

By Meghana Keshavan

The READOUT
The Readout

Breaking down the big Alzheimer’s blowup & CRISPR-cancer roller coaster

By Damian Garde

The READOUT
The Readout

‘Real world evidence’ put to the test & Pfizer partners again

By Damian Garde

The READOUT
The Readout

When tissue turns to bone & a ’Vant first

By Elizabeth Cooney

The READOUT
The Readout

Cholesterol treatment results & The Onion for DNA

By Rebecca Robbins

The READOUT
The Readout

PhaseBio’s NEJM spotlight & CRISPRing AIDS

By Damian Garde

The READOUT
The Readout

Gate-crashing investor conferences & Biogen’s billion-dollar question

By Damian Garde

The READOUT
The Readout

Cardiology’s pulse-check & the future of Insys

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy